ReviewFrontiers in immunology2025
Integrin alpha L: structure, cellular functions, and emerging role in human diseases.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrin Signaling Imbalance in Periodontitis: A Stage-Dependent Link Between Inflammation, Bone Resorption and Regenerative Failure.Biomolecules · 2026Review
- Is hidradenitis suppurativa more an autoinfection than pure autoinflammation?Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an integral component of Lymphocyte Function-associated Antigen 1 (LFA-1), Integrin α L is crucial for the processes of leukocyte adhesion and migration. It engages in specific interactions with Inter-Cellular Adhesion Molecules (ICAMs), thereby playing a significant role in intercellular adhesion, signal transduction, immune response regulation, inflammatory pathways, and the intricate formation of the tumor microenvironment. While preliminary studies have begun to elucidate the phenotypic diversity and bioinformatic characteristics of Integrin α L across various diseases, there remains a paucity of comprehensive reviews addressing the functional roles and underlying mechanisms of Integrin α L in different pathological contexts. This review aims to delineate the fundamental structure and function of Integrin α L, while also summarizing the relationship between its expression patterns and functional attributes with respect to the invasive potential, metastatic capabilities, immune evasion strategies, and clinical outcomes of tumor cells and patients across a spectrum of tumor types. Furthermore, we highlight the significant involvement of Integrin α L in non-tumor-related diseases, including atherosclerosis, systemic sclerosis, depression, and rheumatoid arthritis. Additionally, we assess the potential of Integrin α L as a molecular biomarker for the diagnosis of specific diseases and tumors, which may pave the way for novel therapeutic targets in the treatment of associated conditions and malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.